A carregar...

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients

OBJECTIVES: Emerging data suggest that the combination of tacrolimus and the CCR5 antagonist maraviroc, both cytochrome P450-3A4 substrates, may be effective in preventing graft-versus-host disease in patients undergoing allogeneic HSCT. This study evaluated whether a pharmacokinetic interaction exi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Antimicrob Chemother
Main Authors: Ganetsky, Alex, Miano, Todd A., Hughes, Mitchell E., Vonderheide, Robert H., Porter, David L., Reshef, Ran
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4472330/
https://ncbi.nlm.nih.gov/pubmed/25881619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv082
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!